期刊
EXPERT OPINION ON BIOLOGICAL THERAPY
卷 21, 期 4, 页码 473-486出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14712598.2021.1843628
关键词
Mesothelin; tumor-associated antigen; car-T cells; solid tumors; mesothelioma; immunotherapy; cancer; tumor microenvironment
资金
- CRIS Cancer Foundation
- NCI [PO1-CA217805]
- Novartis
- Tmunity
Initial trials with anti-MSLN CAR-T cells have shown safety but limited efficacy. Enhancing tumor infiltration and persistence, improving safety profiles, combining with standard therapies, and utilizing regional delivery routes could potentially make anti-MSLN CAR-T cells more effective in treating solid malignancies.
Introduction: Mesothelin (MSLN) is a tumor differentiation antigen normally restricted to the body's mesothelial surfaces, but significantly overexpressed in a broad range of solid tumors. For this reason, MSLN has emerged as an important target for the development of novel immunotherapies. This review focuses on anti-MSLN chimeric antigen receptor (CAR) T cell immunotherapy approaches. Areas covered: A brief overview of MSLN as a therapeutic target and existing anti-MSLN antibody-based drugs and vaccines is provided. A detailed account of anti-MSLN CAR-T cell approaches utilized in preclinical models is presented. Finally, a comprehensive summary of currently ongoing and completed anti-MSLN CAR-T cell clinical trials is discussed. Expert opinion: Initial trials using anti-MSLN CAR-T cells have been safe, but efficacy has been limited. Employing regional routes of delivery, introducing novel modifications leading to enhanced tumor infiltration and persistence, and improved safety profiles and combining anti-MSLN CAR-T cells with standard therapies, could render them more efficacious in the treatment of solid malignancies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据